BridgeBio has demonstrably advanced the development of a new therapy for cardiac amyloidosis, utilizing the investigational drug. Preliminary clinical information indicates potential improvements for patients affected https://attr-cm801600.liberty-blog.com/42415834/bridgebio-improves-attr-cm-treatment-with-the-therapy